Compare TLX & RHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLX | RHI |
|---|---|---|
| Founded | 2015 | 1948 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | TLX | RHI |
|---|---|---|
| Price | $9.02 | $27.59 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 7 |
| Target Price | $21.00 | ★ $40.00 |
| AVG Volume (30 Days) | 115.0K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-28-2026 |
| Dividend Yield | N/A | ★ 8.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.04 | ★ 1.54 |
| Revenue | $664,225,558.00 | ★ $5,458,499,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.14 |
| P/E Ratio | $284.97 | ★ $17.95 |
| Revenue Growth | ★ 55.35 | N/A |
| 52 Week Low | $8.76 | $25.22 |
| 52 Week High | $30.36 | $78.41 |
| Indicator | TLX | RHI |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 50.93 |
| Support Level | $9.37 | $26.32 |
| Resistance Level | $10.03 | $28.01 |
| Average True Range (ATR) | 0.25 | 0.80 |
| MACD | -0.00 | 0.22 |
| Stochastic Oscillator | 7.65 | 67.59 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.